摘要:In an environment of real world evidence, patient reported outcomes, expanding expedited and conditional review pathways for the treatment not only for cancers, but for a broad spectrum of serious and life-threatening diseases, we must care more than ever about pharmacovigilance via more regular and creative risk management plans to be sure, but also through a more diligent effort to understand just what “safety and surveillance” is about in the 21 st century. At least part of the solution lies with something called “Artificial Intelligence.”
其他摘要:In an environment of real world evidence, patient reported outcomes, expanding expedited and conditional review pathways for the treatment not only for cancers, but for a broad spectrum of serious and life-threatening diseases, we must care more than ever about pharmacovigilance via more regular and creative risk management plans to be sure, but also through a more diligent effort to understand just what “safety and surveillance” is about in the 21 st century. At least part of the solution lies with something called “Artificial Intelligence.”
关键词:Pharmacovigilance; Artificial Intelligence; Drug Safety